Adverum Biotechnologies (NASDAQ:ADVM – Get Free Report) and Metagenomi (NASDAQ:MGX – Get Free Report) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their dividends, earnings, profitability, institutional ownership, analyst recommendations, valuation and risk.
Insider and Institutional Ownership
48.2% of Adverum Biotechnologies shares are held by institutional investors. 6.0% of Adverum Biotechnologies shares are held by company insiders. Comparatively, 17.8% of Metagenomi shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Analyst Ratings
This is a breakdown of current recommendations and price targets for Adverum Biotechnologies and Metagenomi, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Adverum Biotechnologies | 0 | 1 | 4 | 0 | 2.80 |
| Metagenomi | 0 | 0 | 4 | 0 | 3.00 |
Volatility & Risk
Adverum Biotechnologies has a beta of 0.71, indicating that its stock price is 29% less volatile than the S&P 500. Comparatively, Metagenomi has a beta of -0.33, indicating that its stock price is 133% less volatile than the S&P 500.
Profitability
This table compares Adverum Biotechnologies and Metagenomi’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Adverum Biotechnologies | N/A | -65.14% | -40.52% |
| Metagenomi | -134.27% | -43.23% | -18.86% |
Earnings & Valuation
This table compares Adverum Biotechnologies and Metagenomi”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Adverum Biotechnologies | $1.00 million | 62.05 | -$117.17 million | ($6.40) | -0.46 |
| Metagenomi | $45.26 million | 1.38 | -$68.25 million | ($2.11) | -0.79 |
Metagenomi has higher revenue and earnings than Adverum Biotechnologies. Metagenomi is trading at a lower price-to-earnings ratio than Adverum Biotechnologies, indicating that it is currently the more affordable of the two stocks.
Summary
Metagenomi beats Adverum Biotechnologies on 7 of the 13 factors compared between the two stocks.
About Adverum Biotechnologies
Adverum Biotechnologies, Inc., a clinical-stage company, develops gene therapy product candidates to treat ocular diseases. Its lead product candidate is ixoberogene soroparvovec (ADVM-022), a single intravitreal injection gene therapy candidate used for the treatment of patients with wet age-related macular degeneration and diabetic macular edema which is in phase 2 clinical trials. The company is developing ADVM-062 (AAV.7m8-L-opsin), a novel gene therapy product candidate for the treatment of blue cone monochromacy via a single IVT injection. Adverum Biotechnologies, Inc. has license and collaboration agreements with University of California; GenSight Biologics; Lexeo Therapeutics; and Virovek, Inc. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was incorporated in 2006 and is headquartered in Redwood City, California.
About Metagenomi
Metagenomi, Inc., a genetic medicines company, develops therapeutics for patients using metagenomics-derived genome editing toolbox in the United States. The company's genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems, such as prime editing systems and clustered regularly interspaced short palindromic repeat-associated transposases. It has a strategic collaboration and license agreement with ModernaTX, Inc. focusing on new genome editing system for in vivo human therapeutic applications; a development, option, and license agreement with Affini-T Therapeutics, Inc. to develop and commercialize gene edited T-cell receptor-based therapeutic products in the field of treatment, prevention, or diagnosis of human cancer; and a collaboration and license agreement with Ionis Pharmaceuticals, Inc. to research, develop, and commercialize investigational medicines using genome editing technologies. The company was incorporated in 2016 and is based in Emeryville, California.
Receive News & Ratings for Adverum Biotechnologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adverum Biotechnologies and related companies with MarketBeat.com's FREE daily email newsletter.
